The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA lifted a clinical trial hold on August 20, 2025, allowing trials to resume for companies including Sangamo Therapeutics and Bluebird.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Rocket
Nothing else this week.
-
Sangamo Therapeutics
American biotechnology company
Nothing else this week.
Related events
- FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
Coverage
Newest first; wire copies grouped- BioPharma DiveRocket can resume gene therapy trial after FDA lifts hold This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newslet